QualityStocksNewsBreaks Archives - Page 252 of 1506

MondayMar 04, 2024 12:39 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Weight-Loss Results in Animal Study, Begins Eight-Week Follow-Up Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, is reporting glucose reduction and weight-loss results in a testing of its wholly owned and patented DehydraTECH-CBD formulation. According to the announcement, when administered to rodents in an eight-week study, DehydraTech-CBD resulted in weight loss of 7% and a reduction of 19.9% (p<0.05) in blood glucose. As a result, Lexaria has now signed contracts to begin a large, multiweek animal study that will substantially progress its DehydraTECH-GLP-1 and DehydraTECH-CBD weight-loss investigations. In addition, the announcement also noted that the company had published results of a human study, which showed that a single…

MondayMar 04, 2024 12:13 pm

QualityStocksNewsBreaks – Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF) (FSE: P2QM) Reports Amended Iska Iska Payment Schedule

Eloro Resources (TSX: ELO) (OTCQX: ELRRF) (FSE: P2QM), a leading exploration and mine development company, has amended the payment schedule for the remaining $10 million needed for the company to earn a 100% interest in the Iska Iska silver-tin polymetallic project in the Potosi Department, which is located in southern Bolivia. The amendment was made with the agreement of Empresa Minera Villegas S.R.L., which is the title holder of the Iska Iska project. According to the announcement, Eloro’s Bolivian subsidiary, Minera Tupiza S.R.L., has made advance payments of $4.9 million to date toward the $10 million option payment with the…

MondayMar 04, 2024 11:54 am

QualityStocksNewsBreaks — Appia Rare Earths & Uranium Corp. (CSE: API) (OTCQX: APAAF) (FSE: A0I0) Reports on MRE, Announces Participation at Upcoming Mining Event

Appia Rare Earths & Uranium (CSE: API) (OTCQX: APAAF) (FSE: A0I0), a publicly traded Canadian company in the rare earth element and uranium sectors, announced that it received an independent maiden Mineral Resource Estimate (“MRE”) for its Brazil ionic adsorption clay project. The maiden MRE shows the PCH project is estimated at 52.8 million tonnes (“Mt”) comprising 6.6 Mt Indicated resource with a grade of 2,513 parts per million total rare earth oxide (“TREO”) and 46.2 Mt Inferred resource with a grade of 2,888 ppm TREO. The MRE indicates that the deposit contains significant concentrations of neodymium, praseodymium, dysprosium and terbium,…

FridayMar 01, 2024 3:30 pm

QualityStocksNewsBreaks – Astrotech Corporation’s (NASDAQ: ASTC) Breakthrough TRACER 1000(TM) Designed to Outperform Currently Used IMS Detectors

Astrotech (NASDAQ: ASTC) is a mass spectrometry company that, through its wholly owned subsidiary 1st Detect, has developed and rolled out the breakthrough TRACER 1000(TM) Explosive Trace Detector (“ETD”). “The world’s first mass spectrometry-based ETD certified by the European Civil Aviation Conference (‘ECAC’), the TRACER 1000(TM) is designed to outperform the ETDs currently used at aviation checkpoints as well as borders, cargo facilities and other secured points around the world. It is powered by the Astrotech Mass Spectrometer (‘AMS’) Technology that is inexpensive, smaller and easier to use when compared to traditional mass spectrometers. The AMS Technology works under ultra-high…

FridayMar 01, 2024 2:45 pm

QualityStocksNewsBreaks – Astiva Health Redefining the Standards of Personalized and Comprehensive Healthcare

Astiva Health, a leading healthcare provider that specializes in delivering personalized and comprehensive solutions to diverse communities, is one of the companies committed to providing robust and stable benefit offerings to a growing number of people looking for the best Medicare options. “In a space where a growing number of individuals are qualifying for Medicare, Astiva Health is differentiating itself as a fast-growing Medicare Advantage Prescription Drug (‘MAPD’) health plan focused on redefining the standards of personalized and comprehensive healthcare. As an indication of its success, Astiva recently reached a key milestone, surpassing the 10,000-member mark… Reaching the milestone –…

FridayMar 01, 2024 2:02 pm

QualityStocksNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Committed to Developing Groundbreaking Therapies, Transformative Solutions

PaxMedica (NASDAQ: PXMD) is a clinical-stage biopharmaceutical company focused on the development of novel anti-purinergic therapies (“APTs”) for the treatment of autism spectrum disorder (“ASD”) and other serious conditions with intractable neurologic symptoms. The company is on a promising path to address unmet medical needs of ASD patients. “The prevalence of ASD in the United States has risen to approximately 1 in 36 children, according to the Centers for Disease Control and Prevention (‘CDC’). There are currently no approved pharmacologic treatments that target the causes and symptoms of ASD – the treatment available on the market addresses symptoms of the…

FridayMar 01, 2024 1:51 pm

QualityStocksNewsBreaks — SenesTech Inc.’s (NASDAQ: SNES) ContraPest(R) Delivers Significant Benefits in Efficacy Studies

SenesTech (NASDAQ: SNES), an animal pest control innovator, created its own unique niche within the pest control market after introducing its non-lethal liquid ContraPest(R) bait. “Instead of poisoning rats, the bait targets fertility reduction in male and female rats, and Evolve(TM) has a similar mechanism of action but in a soft bait presentation preferred over liquids by pest management professionals (‘PMPs’) and residential customers. SenesTech’s products are the first, and still the only, such rat contraceptives for both males and females registered with the U.S. Environmental Protection Agency (‘EPA’) designed to be non-lethal,” a recent article explains. “The company conducted…

FridayMar 01, 2024 12:55 pm

QualityStocksNewsBreaks – Vision Marine Technologies Inc. (NASDAQ: VMAR) Appoints Raffi Sossoyan as New Chief Financial Officer

Vision Marine Technologies Inc. (NASDAQ: VMAR), a trailblazer in electric recreational boating, today announced Raffi Sossoyan as its new chief financial officer (“CFO”). Sossoyan brings a wealth of experience, with over 25 years in global financial and operational leadership. In his recent role as VP, corporate treasury at Velan Inc. (TSX: VLN), a Canadian multinational company, he managed financial operations amidst global sales exceeding US$370 million. According to the announcement, Sossoyan’s tenure as CFO at Valtech Fabrication Inc., where he drove worldwide sales beyond US$50 million, further highlights his capacity to spearhead financial growth and success. “This strategic appointment marks…

FridayMar 01, 2024 12:31 pm

QualityStocksNewsBreaks – Mountain Top Properties Inc. (MTPP) to Tap into Resilient Hamptons’ Real Estate Market

Mountain Top Properties (OTC: MTPP) is a diversified real estate holding company focused on building, acquiring, marketing, and operating assets through its wholly owned affiliates. The company is looking to tap into the strength of the high-end real estate market in the Hamptons. “Despite a high interest rate environment, Hamptons-based real estate has shown remarkable resilience over the past year… Despite seeing a 26% decline in year-over-year sales of individual properties, homes priced between $1 million and $3.5 million – which have historically accounted for the lion share of Hamptons’ property transactions, only witnessed a 21% decline,” a recent article…

FridayMar 01, 2024 12:09 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Cleared to Commence HYPER-H23-1 Clinical Trial

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that the U.S. Food and Drug Administration (“FDA”) has confirmed the effectiveness of the company’s investigational new drug (“IND”) application thereby clearing Lexaria to conduct its planned U.S. Phase 1b hypertension clinical trial HYPER-H23-1 utilizing DehydraTECH-CBD. According to the announcement, the company is pleased to have complied with the FDA’s rules and procedures for clearance to perform this important registrational trial. The company will further announce when it is ready to begin the study, subject to certain conditions, including raising sufficient funding. “This is a significant…

Site Search

Company Search

Category: QualityStocksNewsBreaks